Concepedia

Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition

Vishal Patel, Amit Joharapurkar, Samadhan Kshirsagar, Brijesh Sutariya, Maulik Patel, Dheerendra Pandey, Hiren Patel, Ramchandra Ranvir, Shekhar Kadam, Dipam Patel,

Chemico-Biological Interactions · 2018 · 27 citations · 27 references

DOI

Concepts

References

27

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

, , +16

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Jonathan W. Day, Nickki Ottaway, James T Patterson et al. · Nature Chemical Biology · 2009 · 634 citations · Full text

, , +14

Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice†

Xiaokun Ding, Neeraj K. Saxena, Songbai Lin et al. · Hepatology · 2005 · 551 citations · Full text

, , +17

An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitis

Masahiko Matsumoto, Natsuko Hada, Yoshiyuki Sakamaki et al. · International Journal of Experimental Pathology · 2013 · 522 citations · Full text

, , +17